Skip header and navigation

6 records – page 1 of 1.

Antiepileptic drugs : combination therapy and interactions

https://libcat.nshealth.ca/en/permalink/provcat27219
Majkowski, Jerzy. --Cambridge, UK: Cambridge University Press , c2005.
Available Online
View e-Book
Location
Online
Available Online
View e-Book
Author
Majkowski, Jerzy
Place of Publication
Cambridge, UK
Publisher
Cambridge University Press
Date of Publication
c2005
Physical Description
496 p.
ISBN
6610202834
Subjects (MeSH)
Anticonvulsants
Drug Interactions
Drug Therapy, Combination
Epilepsy - drug therapy
Contents
Cover -- Half-title -- Title -- Copyright -- Contents -- List of contributors -- Foreword -- Foreword -- Acknowledgements -- Part I Introduction -- 1 Combination therapy of diseases: general concepts -- Historical aspects -- Polypharmacy -- Polytherapy -- Epidemiology of combination therapy -- Advantages of combination therapy -- Disadvantages of combination therapy -- Conclusions -- REFERENCES -- 2 Combination therapy with antiepileptic drugs: potential advantages and problems -- Rationale for combination therapy -- Potential advantages of combination therapy -- Evidence of benefits of combination therapy versus monotherapy -- Potential problems with combined AEDs -- Summary -- REFERENCES -- 3 Pharmacogenetic aspects -- Introduction -- Metabolism -- Central pharmacokinetics -- Pharmacodynamics -- Adverse events -- Misconceptions about the use of genetic tests -- REFERENCES -- Part II Pharmacokinetic interactions -- 4 Pharmacokinetic principles and mechanisms of drug interactions -- Introduction -- Mechanisms of drug interactions -- Absorption -- Distribution -- Metabolism -- Elimination -- REFERENCES -- 5 Predictability of metabolic antiepileptic drug interactions -- Principles of drug metabolism -- Major drug-metabolizing enzymes -- Enzyme induction and enzyme inhibition -- In vitro systems for testing drug metabolism and metabolic drug interactions -- Prediction of metabolic drug interactions based on in vitro data -- Crucial factors in predicting in vitro-in vivo correlations -- Conclusions -- REFERENCES -- 6 Influence of food and drugs on the bioavailability of antiepileptic drugs -- Introduction -- General principles -- Interactions with the established AEDs -- Interactions with other AEDs -- REFERENCES -- 7 Interactions between antiepileptic drugs -- Summary -- Introduction -- Interactions between classic AEDs (phenobarbital, phenytoin, primidone, carbamazepine, valproic acid, ethosuximide, methsuximide) and other AEDs -- Interactions between new AEDs and other AEDs -- Therapeutic implications -- REFERENCES -- 8 Interaction between antiepileptic and non-antiepileptic drugs -- Introduction -- Carbamazepine -- Ethosuximide -- Felbamate -- Gabapentin -- Lamotrigine -- Levetiracetam -- Oxcarbazepine -- Phenobarbital -- Phenytoin -- Primidone -- Tiagabine -- Topiramate -- Valproic acid -- Vigabatrin -- Zonisamide -- REFERENCES -- Part III Pharmacodynamic interactions -- 9 Pharmacodynamic principles and mechanisms of drug interactions -- Distinction between pharmacodynamic and pharmacokinetic drug interactions -- Types of pharmacodynamic interaction -- Clinical significance of pharmacodynamic interactions -- Desirable and undesirable pharmacodynamic interactions -- Clinical relevance of pharmacodynamic interactions: monotherapy versus combination therapy -- REFERENCES -- 10 Methods for assessing pharmacodynamic interactions -- Experimental methods -- Clinical methods -- REFERENCES -- 11
Format
e-Book
Location
Online
Less detail

Combination Cancer Therapy : Modulators and Potentiators

https://libcat.nshealth.ca/en/permalink/provcat29068
edited by Gary K. Schwartz. --Totowa, NJ: Humana Press , c2005.
Available Online
View e-Book
Location
Online
Available Online
View e-Book
Author
Schwartz, Gary K
Responsibility
edited by Gary K. Schwartz
Place of Publication
Totowa, NJ
Publisher
Humana Press
Date of Publication
c2005
Series Title
Cancer drug discovery and development
ISBN
9781592598649
Subjects (MeSH)
Drug Therapy, Combination
Neoplasms - drug therapy
Subjects (LCSH)
Oncology
Pharmacy
Format
e-Book
Location
Online
Less detail

Combination Therapy In Dyslipidemia

https://libcat.nshealth.ca/en/permalink/provcat39365
Maciej Banach, editor. --Cham: Springer International Publishing : Imprint: Adis , c2015.
Available Online
View e-Book
Location
Online
Comprising contributions from leading lipidologists from around the world, this book presents the latest and most comprehensive knowledge on the different options for combination therapy of dyslipidemia, and includes discussion of future therapies that are currently in late stages of clinical evaluation. Dyslipidemia is a leading cause of cardiovascular morbidity and mortality and most patients with this condition fail to achieve adequate control of their serum lipid levels with monotherapy. Ho…
Available Online
View e-Book
Other Authors
Banach, Maciej
Responsibility
Maciej Banach, editor
Place of Publication
Cham
Publisher
Springer International Publishing : Imprint: Adis
Date of Publication
c2015
Physical Description
1 online resource (viii, 205 p. : 22 illus., 15 illus. in color)
ISBN
9783319204338
9783319204321 (print ed.)
Subjects (MeSH)
Drug Therapy, Combination
Dyslipidemias - drug therapy
Abstract
Comprising contributions from leading lipidologists from around the world, this book presents the latest and most comprehensive knowledge on the different options for combination therapy of dyslipidemia, and includes discussion of future therapies that are currently in late stages of clinical evaluation. Dyslipidemia is a leading cause of cardiovascular morbidity and mortality and most patients with this condition fail to achieve adequate control of their serum lipid levels with monotherapy. However, recent US and European guideline recommendations, based on randomized, controlled trials, fail to discuss combination therapy options for patients with dyslipidemia. Statins remain the mainstay of drug therapy for hyperlipidemia and chapters in this book specifically examine the role of add-on therapy with different agents modulating the different lipid fractions in the blood, e.g. bile acid sequestrants, fibric acid derivatives (fibrates), omega-3 fatty acids (fish oils), inhibitors of Niemann-Pick C1 like 1 (NPC1L1) protein, cholesteryl ester transfer protein (CETP), apolipoprotein B-100 and microsomal triglyceride transfer protein (MTP), and the emerging proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. There is additional discussion of the role of non-drug therapy options such as nutraceuticals, functional foods and lipoprotein apheresis. The book also discusses the combination of antihypertensive drugs with lipid-lowering drugs in the management of cardiovascular risk in patents with dyslipidemia.
Contents
[publisher supplied] Statins and bile acid resins: is there a place for such a combination? -- Statins and fibrates: should it be recommended? -- Statins and ezetimibe: doubts or bright future? -- Statins and niacin: the end of residual risk therapy? -- Statins and omega-3 fatty acids: what more do we need? -- Statins and CETP inhibitors: anacetrapib and evacetrapib: the last hope? -- Statins and mipomersen: the issue of tolerability? -- Statins and lomitapide: a suitable response for HoFH -- Statins and PCSK9 inhibitors: defining the correct patients -- Other possible drug combination for dyslipidaemia -- Statins and nutraceuticals/functional food: could be they combined? -- Lipid lowering therapy and apheresis: indications and outcomes -- Combination of lipid lowering agents with antihypertensive drugs: a joint fight against the two most important risk factors? -- Not only dyslipidaemia therapy: the time for polypills -- Drug Evaluation: Fenofibrate + simvastatin for the treatment of dyslipidemia: When and for whom? -- Drug Evaluation: Olmesartan medoxomil + rosuvastatin for the treatment of dyslipidemia and concomitant risk factors: A chance for better compliance? -- Conclusions and Take Home Message.
Format
e-Book
Location
Online
Less detail

Drug interaction facts 2015 : the authority on drug interactions

https://libcat.nshealth.ca/en/permalink/provcat38419
editor, David S. Tatro. --St. Louis, MO: Wolters Kluwer Health , 2015.
Call Number
QV 39 D794 2015
Location
Cape Breton Regional
Call Number
QV 39 D794 2015
Other Authors
Tatro, David S.
Responsibility
editor, David S. Tatro
Place of Publication
St. Louis, MO
Publisher
Wolters Kluwer Health
Date of Publication
2015
Physical Description
lviii, 2486 p.
ISBN
9781574393637 (pbk.)
1574393634 (pbk.)
Subjects (MeSH)
Drug Interactions
Drug Therapy, Combination
Subjects (LCSH)
Drug interactions--Handbooks, manuals, etc.
Chemotherapy, Combination--Handbooks, manuals, etc.
Format
Book
Location
Cape Breton Regional
Less detail

Hyperthermic Oncology from Bench to Bedside

https://libcat.nshealth.ca/en/permalink/provcat40453
Satoshi Kokura, Toshikazu Yoshikawa, Takeo Ohnishi, editors. --Singapore: Springer , c2016.
Available Online
View e-Book
Location
Online
This comprehensive work broadens readers' understanding of the rudimentary mechanism of the anti-cancer effect of hyperthermia. It also presents state-of-the-art clinical outcomes by hyperthermia treatment of cancer. In the past few decades, basic and clinical research have shown through in vitro experiments that hyperthermia inhibits epithelial-mesenchymal transition (EMT), resulting in the prevention of metastasis. It also has been learned that hyperthermia shows its superior benefit when app…
Available Online
View e-Book
Other Authors
Kokura, Satoshi
Yoshikawa, Toshikazu
Ohnishi, Takeo
Responsibility
Satoshi Kokura, Toshikazu Yoshikawa, Takeo Ohnishi, editors
Place of Publication
Singapore
Publisher
Springer
Date of Publication
c2016
Physical Description
1 online resource (x, 444 p. : 155 illus., 85 illus. in color)
ISBN
9789811007194
9789811007170 (print ed.)
Subjects (MeSH)
Drug Therapy, Combination
Hot Temperature
Hyperthermia, Induced - methods
Neoplasms - therapy
Radiotherapy - methods
Abstract
This comprehensive work broadens readers' understanding of the rudimentary mechanism of the anti-cancer effect of hyperthermia. It also presents state-of-the-art clinical outcomes by hyperthermia treatment of cancer. In the past few decades, basic and clinical research have shown through in vitro experiments that hyperthermia inhibits epithelial-mesenchymal transition (EMT), resulting in the prevention of metastasis. It also has been learned that hyperthermia shows its superior benefit when applied in combination with radiation therapy, chemotherapy, or various immunotherapies as treatments of several types of carcinoma. The chapters here from expert contributors describe the details of their research for each type of cancer. This book provides not only an overview and the current status of hyperthermia but also its future perspectives. Therefore this volume will greatly benefit oncologists, radiologists and radiology technologists, and chemotherapists who are involved in immunotherapy for all kinds of cancer.
Contents
Part I. Basic Science in Cultured Cells -- 1. Introduction -- 2. Induction of oxidative stress by hyperthermia and enhancement of hyperthermia-induced apoptosis by oxidative stress modification -- 3. Molecular Damage: Hyperthermia Alone -- 4. Roles of HSF1 and Heat Shock Proteins in Cancer -- 5. Cellular Responses in Signal Transduction Pathways Induced by Hyperthermia -- 6. Cell cycle responses to hyperthermia -- 7. Thermo-tolerance -- 8. Enhancement of Hyperthermia on Radio-sensitivity -- 9. Inhibition of DNA repair system activity -- 10. Enhancement of Hyperthermia on Anti-tumor Drug Sensitivity -- 11. Inhibition of epithelial-to-mesenchymal transition (EMT) by hyperthermia -- Part II. Basic Science in Whole Body -- 12. Potentiating Immune System by Hyperthermia -- 13. Magnetic Nanoparticle-Mediated Hyperthermia and Induction of Anti-Tumor Immune Responses -- 14. Tumor Microenvironment and Hyperthermia -- Part III. Clinical Science in Cancer Patients -- 15. Hyperthermia Alone -- 16. Combination by Hyperthermia and Radiation (and Chemotherapy): Oral and Maxillofacial Cancer -- 17. Combination by Hyperthermia and Radiation (and Chemotherapy): Lung Cancer -- 18. Efficacy of hyperthermia in combination with radiation therapy for breast cancer -- 19. Combination by Hyperthermia and Radiation: Esophageal Cancer -- 20. Combination by Hyperthermia and Radiation (and Chemotherapy): Gynecology Cancer -- 21. Combination by Hyperthermia and Radiation and Chemotherapy: Soft Tissue Sarcoma -- 22. Combination by Hyperthermia and Chemotherapy: Lung Cancer -- 23. Combination by Hyperthermia and Chemotherapy: Breast Cancer -- 24. Combination by Hyperthermia and Chemotherapy: Esophageal Cancer -- 25. Combination by Hyperthermia and Chemotherapy: Liver Cancer -- 26. Hyperthermia Combined with Chemotherapy: Pancreatic Cancer -- 27. Effect of hyperthermia in combination with chemotherapy and radiation therapy for treatment of urological cancer (prostate cancer and urothelial cancer) -- 28. Combination by Hyperthermia and Surgery -- 29. Combining Hyperthermia and Immunotherapy: NK Therapy and Hyperthermia -- 30. Combination by Hyperthermia and Immunotherapy: DC Therapy and Hyperthermia -- 31. Effects of fever-range hyperthermia on T cell-mediated immunity: possible combination of hyperthermia and T cell-based cancer immunotherapy -- 32. Combination of Hyperthermia and Immunotherapy: Hyperthermia and Naive T-cell Therapy -- 33. HIPEC for Peritoneal Dissemination -- 34. A new comprehensive treatment for peritoneal metastases using cytoreductive surgery combined with hyperthermic intraperitoneal chemoperfusion -- 35. Non-invasive Temperature Moniterring -- 36. Development of Heating Device -- 37. Epilogue.
Format
e-Book
Location
Online
Less detail

Management of castration resistant prostate cancer

https://libcat.nshealth.ca/en/permalink/provcat34052
Fred Saad, Mario A. Eisenberger, editors. --New York: Humana Press , c2014.
Available Online
View e-Book
Location
Online
This volume provides new data about the molecular biology of CRPC and a review of the definition, staging and prognostic factors that define CRPC. The book features an in-depth review of proven therapeutic options, including bone-targeted therapies, immunotherapy, chemotherapy and hormonal based therapies. Combination therapy as well as novel targeted approaches presently under investigation are also reviewed. The text provides up-to-date guidelines and algorithms for the management of CRPC bas…
Available Online
View e-Book
Other Authors
Saad, Fred
Eisenberger, Mario A.
Responsibility
Fred Saad, Mario A. Eisenberger, editors
Place of Publication
New York
Publisher
Humana Press
Date of Publication
c2014
Physical Description
1 online resource (xvi, 337 pages)
Series Title
Current clinical urology
ISBN
9781493911769 (electronic bk.)
9781493911752
Subjects (MeSH)
Drug Therapy, Combination
Molecular Targeted Therapy
Prostatic Neoplasms, Castration-Resistant - metabolism
Prostatic Neoplasms, Castration-Resistant - therapy
Receptors, Androgen - therapeutic use
Subjects (LCSH)
Prostate - Cancer - Treatment
Oncology
Interventional radiology
Abstract
This volume provides new data about the molecular biology of CRPC and a review of the definition, staging and prognostic factors that define CRPC. The book features an in-depth review of proven therapeutic options, including bone-targeted therapies, immunotherapy, chemotherapy and hormonal based therapies. Combination therapy as well as novel targeted approaches presently under investigation are also reviewed. The text provides up-to-date guidelines and algorithms for the management of CRPC based on international guidelines presently available as well as evidence-based medicine.
Contents
Part I. Castrate-Resistant Prostate Cancer: Clinical and Biological Considerations -- 1. Introduction—Castration Resistant Prostate Cancer: A Rapidly Expanding Clinical State and a Model for New Therapeutic Opportunities -- 2. Evolution of Clinical States and the Castration Resistant Clinical Paradigm -- 3. Molecular Mechanisms of Prostate Cancer Progression After Castration -- 4. New Imaging Modalities -- Part II. Treatment: The Androgen Receptor Signaling Axis Biology and Therapeutic Opportunities, Systemic Chemotherapy, Immunotherapy, Bone Targeted Approaches and Radiopharmaceuticals -- 5. Androgen Receptor Biology in Castration Resistant Prostate Cancer -- 6. The Androgen Receptor as a Therapeutic Target for Castration-Resistant Prostate Cancer -- 7. Approaches Targeting Androgen Synthesis (CYP 17 Inhibitors) -- 8. Cytotoxic Chemotherapy (Taxanes and Taxane Combinations) -- 9. The Emerging Role of Immunotherapy in Castrate- Resistant Prostate Cancer -- 10. Bone-Targeted Therapy: Rationale and Current Status -- 11. Radium-223 and Other Radiopharmaceuticals in Prostate Cancer -- Part III. New Drug Development: Clinical Trials Design in CRPC -- 12. Introduction -- 13. Phase I–II Targeted Treatments -- 14. Defining Clinical Endpoints in Castration-Resistant Prostate Cancer -- Part IV. New Drug Development: Specific Targets -- 15. Angiogenesis Inhibition in Castration-Resistant Prostate Cancer -- 16. Co-targeting Adaptive Survival Pathways -- 17. Targeting the PI3K/AKT/mTOR Pathway in Prostate Cancer -- 18. PARP Inhibitors -- 19. Targeting C-Met/VEGF in Castration Resistant Prostate Cancer -- 20. Epigenetics in Castration Resistant Prostate Cancer -- 21. Undifferentiated Prostate Cancer and the Neuroendocrine Phenotype -- Part V. Clinical Management Aspects -- 22. Strategies Addressing Quality of Life: Management of Patient-Reported Outcomes and Symptoms -- 23. Evidence-Based Therapeutic Approaches for mCRPC Patients: Rational Sequence of Standard Treatment Options and Design for Future Drug Development.
Format
e-Book
Location
Online
Less detail

6 records – page 1 of 1.